Accovion, the European clinical research organisation based in Eschborn, Germany, has extended its reach into “key strategic territory” with a new subsidiary (Accovion Ltd) in Windsor, UK.
The company, which supports local and global clinical research projects at all phases of development for pharmaceutical, biotechnology and medical device companies, said the new subsidiary “tangibly underscores Accovion’s growth target”.
Not only has the UK always been a key strategic territory for the company but Accovion’s expanding regulatory portfolio and growing involvement in device pharmacovigilance and health economics meant it was “imperative for us to be firmly implanted in London”, noted chief operating officer Ivana Waller.
The company was already established at two locations in Germany (Eschborn and Marburg) as well as in the Czech Republic, Poland Romania and Russia. The Czech and Russian subsidiaries were opened last December.
The UK subsidiary, which will be headed up by newly appointed managing director Carl Naraynassamy, “consolidates our presence in Europe and affords us a sure platform to access the considerable local clinical research talent and respond even better to our clients’ growing needs”, Waller commented.
As previously stated, Accovion’s strategic plan for 2011 includes formalising activities in a number of other European countries by setting up additional subsidiaries.
The company’s service offering includes project planning and management, clinical trial execution, clinical monitoring, data management, adverse event management, biostatistics and statistical programming, medical writing and electronic publishing.
